Racial Disparities in Utilization of Specialist Care and Medications in Inflammatory Bowel Disease

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - modelling outcomes in active luminal and fistulizing disease in adults

(2010) J. LINDSAY et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data

(2009) K. BODGER et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Racial Clustering and Access to Colorectal Surgeons, Gastroenterologists, and Radiation Oncologists by African Americans and Asian Americans in the United States

(2009) Awori J. Hayanga   ARCHIVES OF SURGERY

Time Trends in Therapies and Outcomes for Adult Inflammatory Bowel Disease, Northern California, 1998–2005

(2009) Lisa J. Herrinton et al.   GASTROENTEROLOGY

Residential Segregation and Access to Surgical Care by Minority Populations in US Counties

(2009) Awori Jeremiah Hayanga et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis

(2008) H. H. TSAI et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

(2008) Brian G. Feagan et al.   GASTROENTEROLOGY

How Many Are Underinsured? Trends Among U.S. Adults, 2003 And 2007

(2008) Cathy Schoen et al.   HEALTH AFFAIRS

Patterns of infliximab use among Crohnʼs disease patients in a community setting

(2008) Alice R. Pressman et al.   INFLAMMATORY BOWEL DISEASES

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET

How expensive is inflammatory bowel disease? A critical analysis

(2008) Selwyn Odes   WORLD JOURNAL OF GASTROENTEROLOGY

Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study

(2007) Mark H. Flasar et al.   INFLAMMATORY BOWEL DISEASES